人原代NK细胞敲除CD38可消除达雷妥尤单抗诱导的同室相残并增强其效应活性
多发性骨髓瘤常表达CD38,达雷妥尤单抗(DARA)疗效短暂,机制涉及CD38下调、补体抑制蛋白过表达及DARA清除CD38高表达NK细胞导致抗体依赖细胞毒作用(ADCC)受损。本研究用CRISPR/Cas9在体外扩增的外周血NK细胞中敲除CD38(CD38KO),发现其完全抵抗DARA诱导的同室相残,在DARA预处理免疫缺陷小鼠中持久性更优,对CD38表达骨髓瘤细胞系及原代细胞的ADCC增强,并具独特代谢重编程。
要点
- CD38KO NK细胞完全抵抗DARA诱导的同室相残。
- CD38KO NK细胞在DARA预处理免疫缺陷小鼠中持久性更优。
- CD38KO NK细胞对CD38表达骨髓瘤细胞系及原代细胞的ADCC增强。
核心结论
- 体外扩增CD38KO NK细胞的过继免疫治疗有潜力增强DARA在多发性骨髓瘤中的活性,提供概念验证。
研究设计与样本
- 研究使用CRISPR/Cas9系统在体外扩增的外周血NK细胞中敲除CD38,并在免疫缺陷小鼠及骨髓瘤细胞系和原代细胞中评估功能。
主要发现
- CD38KO NK细胞完全抵抗DARA诱导的同室相残。
- CD38KO NK细胞在DARA预处理的免疫缺陷小鼠中持久性更优。
- CD38KO NK细胞对CD38表达骨髓瘤细胞系和原代骨髓瘤细胞的ADCC活性增强。
- 转录组和细胞代谢分析显示CD38KO NK细胞具有独特代谢重编程,线粒体呼吸能力更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a plasma cell neoplasm that commonly expresses CD38. Daratumumab (DARA), a human monoclonal antibody targeting CD38, has significantly improved the outcome of patients with relapsed or refractory MM, but the response is transient in most cases. Putative mechanisms of suboptimal efficacy of DARA include downregulation of CD38 expression and overexpression of complement inhibitory proteins on MM target cells as well as DARA-induced depletion of CD38high natural killer (NK) cells resulting in crippled antibody-dependent cellular cytotoxicity (ADCC). Here, we tested whether maintaining NK cell function during DARA therapy could maximize DARA-mediated ADCC against MM cells and deepen the response. We used the CRISPR/Cas9 system to delete CD38 (CD38KO) in ex vivo expanded peripheral blood NK cells. These CD38KO NK cells were completely resistant to DARA-induced fratricide, showed superior persistence in immune-deficient mice pretreated with DARA, and enhanced ADCC activity against CD38-expressing MM cell lines and primary MM cells. In addition, transcriptomic and cellular metabolic analysis demonstrated that CD38KO NK cells have unique metabolic reprogramming with higher mitochondrial respiratory capacity. Finally, we evaluated the impact of exposure to all-trans retinoic acid (ATRA) on wild-type NK and CD38KO NK cell function and highlighted potential benefits and drawbacks of combining ATRA with DARA in patients with MM. Taken together, these findings provide proof of concept that adoptive immunotherapy using ex vivo expanded CD38KO NK cells has the potential to boost DARA activity in MM.
引用
- Naeimi Kararoudi M, Nagai Y, Elmas E, et al. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020. PMID: 32603414. doi:10.1182/blood.2020006200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。